Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 5/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 4/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12041500 | 0.86 | S1PR1 (0.54) | P2RY14SIGMAR1CHRM2CHRM5CHRM1 | |
| SCHEMBL382502 | 0.85 | S1PR1 (0.53) | P2RY14SIGMAR1CHRM2CHRM5CHRM1 | |
| SCHEMBL12041495 | 0.82 | SMN1; SMN2 (0.49) | P2RY14SIGMAR1CHRM2CHRM5CHRM1 | |
| Lithium Ion SCHEMBL381730 | 0.79 | CARM1 (0.63) | — | |
| Lithium Ion SCHEMBL9983742 | 0.78 | CA2 (0.56) | DRD2DRD4 | |
| Lithium Ion SCHEMBL9983643 | 0.77 | S1PR1 (0.56) | SIGMAR1DRD2 | |
| SCHEMBL6367741 | 0.75 | DRD2 (0.45) | P2RY14DRD2GRM2DRD4HTR2C | |
| SCHEMBL6827382 | 0.75 | DRD2 (0.49) | SIGMAR1DRD2GRM2DRD4HTR2C | |
| SCHEMBL6889969 | 0.74 | DRD2 (0.54) | P2RY14CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL2636716 | 0.73 | LIPE (0.52) | P2RY14SIGMAR1CHRM2CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096524-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| EP-2408742-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-09-03 | — | — | EP | disclosed |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | P2RY14 325/4885SIGMAR1 4049/4885CHRM2 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.